PIPERACILLIN SODIUM,TAZOBACTAM SODIUM

N/A

Manufactured by Fresenius Kabi USA, LLC

44,977 FDA adverse event reports analyzed

Last updated: 2026-04-14

About PIPERACILLIN SODIUM,TAZOBACTAM SODIUM

PIPERACILLIN SODIUM,TAZOBACTAM SODIUM is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Fresenius Kabi USA, LLC. The most commonly reported adverse reactions for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM include DRUG INEFFECTIVE, OFF LABEL USE, ACUTE KIDNEY INJURY, PYREXIA, DIARRHOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM.

Top Adverse Reactions

DRUG INEFFECTIVE2,726 reports
OFF LABEL USE2,486 reports
ACUTE KIDNEY INJURY1,855 reports
PYREXIA1,628 reports
DIARRHOEA1,045 reports
CONDITION AGGRAVATED1,012 reports
THROMBOCYTOPENIA955 reports
PNEUMONIA931 reports
NEUTROPENIA909 reports
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS865 reports
FEBRILE NEUTROPENIA815 reports
RASH768 reports
SEPSIS738 reports
DYSPNOEA737 reports
SEPTIC SHOCK737 reports
DRUG INTERACTION716 reports
HYPOTENSION689 reports
NAUSEA665 reports
VOMITING640 reports
MULTIPLE ORGAN DYSFUNCTION SYNDROME639 reports
RESPIRATORY FAILURE612 reports
PRODUCT USE IN UNAPPROVED INDICATION590 reports
ANAEMIA520 reports
RASH MACULO PAPULAR496 reports
PANCYTOPENIA489 reports
ABDOMINAL PAIN483 reports
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION422 reports
TOXIC EPIDERMAL NECROLYSIS422 reports
FATIGUE419 reports
EOSINOPHILIA405 reports
PLATELET COUNT DECREASED393 reports
COVID 19388 reports
PRURITUS383 reports
LEUKOPENIA377 reports
DEATH373 reports
RENAL FAILURE373 reports
CHOLESTASIS364 reports
MALAISE359 reports
RENAL IMPAIRMENT343 reports
BLOOD CREATININE INCREASED319 reports
PAIN318 reports
CHILLS316 reports
GENERAL PHYSICAL HEALTH DETERIORATION315 reports
COUGH311 reports
INFECTION311 reports
PLEURAL EFFUSION309 reports
ASTHENIA306 reports
CLOSTRIDIUM DIFFICILE COLITIS306 reports
DISEASE PROGRESSION304 reports
ERYTHEMA302 reports
HEPATIC CYTOLYSIS297 reports
TUBULOINTERSTITIAL NEPHRITIS296 reports
MUCOSAL INFLAMMATION292 reports
CYTOKINE RELEASE SYNDROME288 reports
DRUG RESISTANCE288 reports
CARDIAC ARREST286 reports
TACHYCARDIA284 reports
DRUG HYPERSENSITIVITY277 reports
CONFUSIONAL STATE272 reports
PATHOGEN RESISTANCE270 reports
HYPOKALAEMIA260 reports
TOXICITY TO VARIOUS AGENTS259 reports
CLOSTRIDIUM DIFFICILE INFECTION255 reports
AGRANULOCYTOSIS254 reports
DECREASED APPETITE254 reports
ACUTE RESPIRATORY DISTRESS SYNDROME253 reports
ALANINE AMINOTRANSFERASE INCREASED253 reports
HYPOXIA252 reports
URINARY TRACT INFECTION251 reports
HYPERSENSITIVITY245 reports
INTERSTITIAL LUNG DISEASE242 reports
PRODUCT USE ISSUE241 reports
HYPERTENSION237 reports
CARDIAC FAILURE231 reports
HEADACHE230 reports
TREATMENT FAILURE228 reports
HAEMOGLOBIN DECREASED226 reports
BACK PAIN223 reports
SEIZURE223 reports
DRUG INDUCED LIVER INJURY221 reports
C REACTIVE PROTEIN INCREASED219 reports
ARTHRALGIA217 reports
CELLULITIS216 reports
STAPHYLOCOCCAL INFECTION213 reports
ENCEPHALOPATHY212 reports
HEPATIC FAILURE212 reports
STEVENS JOHNSON SYNDROME209 reports
APLASTIC ANAEMIA207 reports
LEUKOCYTOSIS206 reports
BRONCHOPULMONARY ASPERGILLOSIS204 reports
HEPATIC ENZYME INCREASED204 reports
METABOLIC ACIDOSIS203 reports
RENAL TUBULAR NECROSIS203 reports
CANDIDA INFECTION201 reports
WEIGHT DECREASED200 reports
ACUTE GENERALISED EXANTHEMATOUS PUSTULOSIS197 reports
CHEST PAIN196 reports
WHITE BLOOD CELL COUNT DECREASED196 reports
ANAPHYLACTIC REACTION195 reports
NEPHROPATHY TOXIC195 reports

Report Outcomes

Out of 24,685 classified reports for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM:

Serious 97.7%Non-Serious 2.3%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male13,142 (58.5%)
Female9,307 (41.4%)
Unknown24 (0.1%)

Reports by Age

Age 74549 reports
Age 65543 reports
Age 71506 reports
Age 63484 reports
Age 64483 reports
Age 62481 reports
Age 70481 reports
Age 67480 reports
Age 61477 reports
Age 68473 reports
Age 72464 reports
Age 69451 reports
Age 73447 reports
Age 75441 reports
Age 60436 reports
Age 58430 reports
Age 66425 reports
Age 76421 reports
Age 59403 reports
Age 56399 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with PIPERACILLIN SODIUM,TAZOBACTAM SODIUM?

This profile reflects 44,977 FDA FAERS reports that mention PIPERACILLIN SODIUM,TAZOBACTAM SODIUM. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM?

Frequently reported terms in FAERS include DRUG INEFFECTIVE, OFF LABEL USE, ACUTE KIDNEY INJURY, PYREXIA, DIARRHOEA, CONDITION AGGRAVATED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures PIPERACILLIN SODIUM,TAZOBACTAM SODIUM?

Labeling and FAERS entries often list Fresenius Kabi USA, LLC in connection with PIPERACILLIN SODIUM,TAZOBACTAM SODIUM. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.